BioNTech SE (NASDAQ:BNTX) Q3 2024 Earnings Conference Call November 4, 2024 8:00 AM ET
Company Participants
Michael Horowicz - Director, Investor Relations
Ugur Sahin - Chief Executive Officer & Co-Founder
Özlem Türeci - Chief Medical Officer & Co-Founder
Jens Holstein - Chief Financial Officer
Ryan Richardson - Chief Strategy Officer
Conference Call Participants
Tazeen Ahmad - Bank of America Securities
Daina Graybosch - Leerink Partners
Suzanne van Voorthuizen - VLK
Terence Flynn - Morgan Stanley
Yaron Werber - TD Cowen
Jessica Fye - JPMorgan Chase
Cory Kasimov - Evercore ISI
Luke Shumway - BMO Capital Markets
Ellie Merle - UBS
Yifeng Liu - HSBC Bank Plc
Simon Baker - Redburn Atlantic
Manos Mastorakis - Deutsche Bank
Jay Olson - Oppenheimer
Operator
Welcome to BioNTech's Third Quarter 2024 Earnings Call.
I would like to hand the call over to Michael Horowicz, Director of Investor Relations. Please go ahead.
Michael Horowicz
Thank you. Good morning and good afternoon. Thank you for joining BioNTech's third quarter 2024 earnings call. As a reminder, the slides we will be using during this call and the corresponding press release we issued this morning can be found in the Investor Relations section of our website.
On the next slide, you will see our forward-looking statements disclaimer. Additional information about these statements and other risks are described in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this call are subject to significant risks and uncertainties and speak only as of the date of this conference call. We undertake no obligation to update or revise any of these statements.
On Slide 3, you can find the agenda for today's call. Today, I am joined by the following members of BioNTech's management team: Ugur Sahin, Chief Executive Officer and Co-Founder; Özlem Türeci, Chief Medical Officer and Co-Founder; Jens Holstein, Chief Financial Officer; and Ryan Richardson, Chief Strategy Officer.
With this, I would like to hand over to Ugur.
Ugur Sahin
Thank you, Michael. Welcome to all those joining us today. I will be keeping my introduction very brief today.
We made significant achievements during the third quarter, including advancements across our oncology pipeline and a strong start to the season for our COVID-19 vaccine franchise. Our progress in this quarter [builds on] (ph) what has already been an impactful year. I would like to highlight achievements in three areas.
First, with regard to our COVID-19 vaccine leadership, we have successfully launched updated vaccines targeting the latest variant. Distribution now underway in multiple regions globally.